Tags : Worldwide

Biotech

ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5

Shots: Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M, $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate In 2019, ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited […]Read More

Pharma

Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement

Shots: Palette to receive global development rights for Nestle’s Deflux, Solesta and Barrigel and will focus on its commercialization. Nestle will continue to develop the license products for Palette The licensed products are developed by using Nestle’s NASHA technology, used for injecting and creating firm gel texture. Additionally, Pharmanest AB will be renamed as Palette […]Read More

Pharma

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize

Shots:  Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution  Company also revealed the reason for keeping the deal undisclosed, as the transaction was under pre-closing confidentiality restrictions The focus of the purchase is to enrich its respiratory units in […]Read More